Screener
iRadimed IRMD Accounts Receivable, Credit Loss Expense (Reversal)
Accounts Receivable, Credit Loss Expense (Reversal) at other companies
Other financials
Where this comes from
Reported directly by iRadimed in its filing.
Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.
The source filing: iRadimed’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029325
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating activities: | ||
| Net income | $5,818 | $4,687 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Allowance for credit losses | 40 | (15) |
| Provision for excess and obsolete inventory | 15 | (38) |
| Depreciation & amortization | 455 | 194 |
| Stock-based compensation | 684 | 826 |
| Deferred income taxes, net | (137) | 130 |
Item 1. Condensed Financial Statements
FAQ
- What is iRadimed's accounts receivable, credit loss expense (reversal)?
- iRadimed (IRMD) reported accounts receivable, credit loss expense (reversal) of $40K in Q1 2026.
- How has iRadimed's accounts receivable, credit loss expense (reversal) changed year-over-year?
- iRadimed's accounts receivable, credit loss expense (reversal) increased by 366.7% year-over-year, from -$15K to $40K.
- What is the long-term trend for iRadimed's accounts receivable, credit loss expense (reversal)?
- Over 3 years (2021 to 2025), iRadimed's accounts receivable, credit loss expense (reversal) has grown at a 82.3% compound annual growth rate (CAGR), from $13.88K to -$84K.
Ask your AI about iRadimed's accounts receivable, credit loss expense (reversal).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude